The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy

Tuesday, March 06, 2012

Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy09:00 EST Tuesday, March 06, 2012ABBOTT PARK, Ill., March 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will collaborate with Merck to evaluate the use of a FISH (fluorescence in situ hybridization)-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy. FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy.    Under terms of the agreement, Abbott will develop a test based on its proprietary FISH technology, intended to identify deletions of the TP53 gene in cancer patients. The Abbott FISH assay will be evaluated in clinical trials to help identify patients more likely to respond favorably to Merck's investigational cancer therapy."Our goal through this collaboration, and others like it, is to ensure that the right medicine gets to the right patient," said Stafford O'Kelly, head of Abbott's molecular diagnostics business.  "As one of the early pioneers in companion diagnostics, we believe that linking genetic testing with drug development at the earliest stages can increase the effectiveness and predictability of medicines and help physicians make more informed treatment decisions."Abbott's portfolio of companion diagnostic tests includes the PathVysion® HER-2 DNA Probe Kit, which represents one of the first examples of innovations in the field of personalized medicine. The test is approved for use in selecting breast cancer patients for whom Herceptin® (trastuzumab) therapy is being considered.  In addition, Abbott's Vysis ALK Break Apart FISH Probe kit was approved in 2011 for use in identifying non-small cell lung cancer patients for XALKORI® (crizotinib) treatment.  Abbott has personalized medicine collaborations in place with a number of pharmaceutical companies, including Pfizer and GlaxoSmithKline.About FISH FISH technology has a variety of uses. It can identify whether too many, or too few, copies of a particular gene are present in the body's cells or whether certain genes have rearrangements that play an active role in disease progression. Cancer diagnostics is one of the fastest growing applications.About Abbott MolecularAbbott Molecular is a leader in molecular diagnostics ? the analysis of DNA and RNA at the molecular level. Abbott Molecular's tests can also detect subtle but key changes in patients' genes and chromosomes and have the potential for earlier detection or diagnosis, provide information relevant to the selection of appropriate therapies, and may improve monitoring of disease progression.  About Abbott Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.SOURCE AbbottFor further information: Media, Cheryl Dodd, +1-847-937-6570, or Financial, Tina Ventura, +1-847-935-9390